IL276383B2 - Treatment of ophthalmologic diseases - Google Patents

Treatment of ophthalmologic diseases

Info

Publication number
IL276383B2
IL276383B2 IL276383A IL27638320A IL276383B2 IL 276383 B2 IL276383 B2 IL 276383B2 IL 276383 A IL276383 A IL 276383A IL 27638320 A IL27638320 A IL 27638320A IL 276383 B2 IL276383 B2 IL 276383B2
Authority
IL
Israel
Prior art keywords
bispecific antibody
treatment
use according
seq
vegf
Prior art date
Application number
IL276383A
Other languages
English (en)
Hebrew (he)
Other versions
IL276383A (en
IL276383B1 (en
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of IL276383A publication Critical patent/IL276383A/en
Publication of IL276383B1 publication Critical patent/IL276383B1/en
Publication of IL276383B2 publication Critical patent/IL276383B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL276383A 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases IL276383B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US201862729333P 2018-09-10 2018-09-10
PCT/EP2019/052704 WO2019154776A1 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Publications (3)

Publication Number Publication Date
IL276383A IL276383A (en) 2020-09-30
IL276383B1 IL276383B1 (en) 2023-09-01
IL276383B2 true IL276383B2 (en) 2024-01-01

Family

ID=65352014

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276383A IL276383B2 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Country Status (12)

Country Link
US (2) US20210139576A1 (enExample)
EP (1) EP3749359A1 (enExample)
JP (5) JP7005772B2 (enExample)
KR (2) KR20240093772A (enExample)
CN (4) CN119733046A (enExample)
AU (3) AU2019219004B2 (enExample)
CA (1) CA3088355A1 (enExample)
IL (1) IL276383B2 (enExample)
MX (1) MX2020007527A (enExample)
SG (1) SG11202006712XA (enExample)
TW (3) TW202535932A (enExample)
WO (1) WO2019154776A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
IL276158B2 (en) 2018-01-26 2024-07-01 Univ California Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
CN119303075A (zh) * 2019-08-06 2025-01-14 豪夫迈·罗氏有限公司 眼科疾病的个性化治疗
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
CN116323663A (zh) * 2020-09-04 2023-06-23 豪夫迈·罗氏有限公司 与vegf-a和ang2结合的抗体及其使用方法
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
EP4313148A4 (en) * 2021-03-30 2025-02-19 Abpro Corporation METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION WITH MULTI-SPECIFIC ANTI-ANG2 X VEGF ANTIBODIES
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP4392038A4 (en) * 2021-08-23 2025-06-11 Avirmax Biopharma Inc. COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014177459A2 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
US20160215045A1 (en) * 2015-01-28 2016-07-28 Eli Lilly And Company VEGFA/Ang2 Compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
SG10202111177VA (en) * 2011-01-13 2021-11-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2859667C (en) 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
RS59263B1 (sr) 2012-04-20 2019-10-31 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
CA3098856C (en) * 2012-08-21 2023-10-17 Opko Pharmaceuticals, Llc Ophthalmic liposome formulations for treating posterior segment disease
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP3230316B1 (en) * 2014-12-11 2022-01-05 Bayer HealthCare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
EP3454903A4 (en) 2016-05-13 2020-08-19 Askgene Pharma, Inc. NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF
AU2017286676B2 (en) * 2016-06-17 2024-07-25 F. Hoffmann La-Roche Ag Purification of multispecific antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014177459A2 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
US20160215045A1 (en) * 2015-01-28 2016-07-28 Eli Lilly And Company VEGFA/Ang2 Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAKRAVARTHY U:, PHASE I TRIAL OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR/ANTI-ANGIOPOIETIN 2 BISPECIFIC ANTIBODY RG7716 FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, 1 November 2017 (2017-11-01) *
JORG T REGULA ET AL:, TARGETING KEY ANGIOGENIC PATHWAYS WITH A BISPECIFIC CROSSMAB OPTIMIZED FOR NEOVASCULAR EYE DISEASES, 14 October 2016 (2016-10-14) *

Also Published As

Publication number Publication date
JP2022046738A (ja) 2022-03-23
CN119909169A (zh) 2025-05-02
KR20240093772A (ko) 2024-06-24
JP2025084977A (ja) 2025-06-03
JP7273204B2 (ja) 2023-05-12
TWI831764B (zh) 2024-02-11
TW202535932A (zh) 2025-09-16
IL276383A (en) 2020-09-30
CA3088355A1 (en) 2019-08-15
AU2025220842A1 (en) 2025-09-11
EP3749359A1 (en) 2020-12-16
KR20200119274A (ko) 2020-10-19
WO2019154776A1 (en) 2019-08-15
TWI885720B (zh) 2025-06-01
CN119770646A (zh) 2025-04-08
MX2020007527A (es) 2020-09-09
IL276383B1 (en) 2023-09-01
CN119733046A (zh) 2025-04-01
JP2025084976A (ja) 2025-06-03
AU2019219004B2 (en) 2025-06-05
JP7005772B2 (ja) 2022-02-10
AU2025220841A1 (en) 2025-09-11
TW202419464A (zh) 2024-05-16
CN111699004A (zh) 2020-09-22
JP7646727B2 (ja) 2025-03-17
JP2021506947A (ja) 2021-02-22
US20210139576A1 (en) 2021-05-13
TW202000700A (zh) 2020-01-01
SG11202006712XA (en) 2020-08-28
JP2023099094A (ja) 2023-07-11
AU2019219004A1 (en) 2020-07-16
US20230416353A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
IL276383B2 (en) Treatment of ophthalmologic diseases
JP2023099094A5 (enExample)
ES2361917T3 (es) Inhibidores del receptor 1 del factor de crecimiento de fibroblastos y procedimiento de tratamiento de los mismos.
US9932397B2 (en) VEGFA/Ang2 Compounds
US10597452B2 (en) Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
JP2017536414A5 (enExample)
JP2020508317A5 (enExample)
JP2016522210A (ja) 抗ｖｅｇｆ抗体およびそれを含む癌または血管新生関連疾患を予防、診断、または治療するための医薬組成物
JP2017534645A5 (enExample)
IL303344A (en) Tetravalent FZD and WNT receptor binding antibody compounds
JP2025530139A (ja) 抗ＦｃＲＮ抗体を用いた慢性炎症性脱髄性多発神経障害の治療方法
CN111094339B (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
RU2017120361A (ru) Антитела к pdgf-b и способы их применения
JP2019521156A5 (enExample)
CN107106676A (zh) 用于治疗肉瘤的组合物和方法
US9580499B2 (en) VEGFR2/Ang2 compounds
CN119264263A (zh) 靶向pd-1和lag3的双特异性抗体及其用途
JP2025521387A (ja) 抗－ｃｄ７３抗体およびｉｌ－２を含む融合タンパク質およびその用途
RU2021125763A (ru) Биспецифическое антитело, специфически связывающееся с vegf и ang2